Glaucoma Genetics: Advancing New Understandings of Glaucoma Pathogenesis

International Ophthalmology Clinics

Volumn 44, Issue 2, 2004, Pages 167-185

  Challa, Pratap ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOCILIN; TRANSCRIPTION FACTOR;

AMINO TERMINAL SEQUENCE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL FEATURE; CONGENITAL GLAUCOMA; DNA POLYMORPHISM; DNA SEQUENCE; FOX C1 GENE; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; HUMAN; IRIS ATROPHY; MULTIFACTORIAL GENETIC DISORDER; MUTATOR GENE; OPEN ANGLE GLAUCOMA; PATHOGENESIS; PETERS ANOMALY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHLEMM CANAL; STRUCTURAL HOMOLOGY; TRABECULAR MESHWORK; VISUAL FIELD DEFECT;

GENETIC SCREENING; GLAUCOMA; HUMANS; MOLECULAR BIOLOGY;

EID: 1942469938     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404420-00011     Document Type: Review

References (148)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80: 389-393.
2. Thylefors B, Negrel AD, Pararajasegaram R, et al. Global data on blindness. Bull World Health Organ. 1995;73:115-121.
3. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266:369-374.
4. Armaly MF. Inheritance of dexamethasone hypertension and glaucoma. Arch Ophthalmol. 1967;77:747-751.
5. Sarfarazi M. Recent advances in molecular genetics of glaucomas. Hum Mol Genet. 1997;6:1667-1677.
6. Tawara A, Inomata H. Developmental immaturity of the trabecular meshwork in juvenile glaucoma. Am J Ophthalmol. 1984;98:82-97.
7. Polansky JR, Fauss DJ, Chen P, et al. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica. 1997;211:126-139.
8. Sheffield VC, Stone EM, Alward WL, et al. Genetic linkage of familial open angle glaucoma to chromosome 1q21-q31. Nat Genet. 1993;4:47-50.
9. Stone EM, Fingert JH, Alward WL, et al. Identification of a gene that causes primary open angle glaucoma. Science. 1997;275:668-670.
10. Allingham RR, Wiggs JL, De La Paz MA, et al. Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1998; 39:2288-2295.
11. Angius A, Spinelli P, Ghilotti G, et al. Myocilin Gln368stop mutation and advanced age as risk factors for late-onset primary open-angle glaucoma. Arch Ophthalmol. 2000;118: 674-679.
12. Fingert JH, Heon E, Liebmann JM, et al. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Hum Mol Genet. 1999;8:899-905.
13. Kennan AM, Mansergh FC, Fingert JH, et al. A novel Asp380Ala mutation in the GLC1A/myocilin gene in a family with juvenile onset primary open angle glaucoma. J Med Genet. 1998;35:957-960.
14. Mabuchi F, Yamagata Z, Kashiwagi K, et al. Analysis of myocilin gene mutations in Japanese patients with normal tension glaucoma and primary open-angle glaucoma. Clin Genet. 2001;59:263-268.
15. Mabuchi F, Yamagata Z, Kashiwagi K, et al. A sequence change (Arg158Gln) in the leucine zipper-like motif region of the MYOC/TIGR protein. J Hum Genet. 2001;46: 85-89.
16. Mansergh FC, Kenna PF, Ayuso C, et al. Novel mutations in the TIGR gene in early and late onset open angle glaucoma. Hum Mutat. 1998;11:244-251.
17. Suzuki R, Hattori Y, Okano K. Promoter mutations of myocilin gene in Japanese patients with open angle glaucoma including normal tension glaucoma. Br J Ophthalmol 2000;84:1078.
18. Taniguchi F, Suzuki Y, Shirato S, et al. The Gly367Arg mutation in the myocilin gene causes adult-onset primary open-angle glaucoma. Jpn J Ophthalmol. 2000;44:445-448.
19. Vasconcellos JP, Melo MB, Costa VP, et al. Novel mutation in the MYOC gene in primary open glaucoma patients. J Med Genet. 2000;37:301-303.
20. Suzuki Y, Shirato S, Taniguchi F, et al. Mutations in the TIGR gene in familial primary open-angle glaucoma in Japan. Am J Hum Genet. 1997;61:1202-1204.
21. Challa P, Herndon LW, Hauser MA, et al. Prevalence of myocilin mutations in adults with primary open-angle glaucoma in Ghana, West Africa. J Glaucoma. 2002;11:416-420.
22. Alward WL, Kwon YH, Khanna CL, et al. Variations in the myocilin gene in patients open-angle glaucoma. Arch Ophthalmol. 2002;120:1189-1197.
23. Shimizu S, Lichter PR, Johnson AT, et al. Age-dependent prevalence of mutations at the GLC1A locus in primary open-angle glaucoma. Am J Ophthalmol. 2000;130:165-177.
24. Kubota R, Kudoh J, Mashima Y, et al. Genomic organization of the human myocilin gene (MYOC) responsible for primary open angle glaucoma (GLC1A). Biochem Biophys Res Commun. 1998;242:396-400.
25. Fingert JH, Ying L, Swiderski RE, et al. Characterization and comparison of the human and mouse GLC1A glaucoma genes. Genome Res. 1998;8:377-384.
26. Kubota R, Noda S, Wang Y, et al. A novel myosin-like protein (myocilin) expressed in the connecting cilium of the photoreceptor: molecular cloning, tissue expression, and chromosomal mapping. Genomics. 1997;41:360-369.
27. Ortego J, Escribano J, Coca-Prados M. Cloning and characterization of subtracted cDNAs from a human ciliary body library encoding TIGR, a protein involved in juvenile open angle glaucoma with homology to myosin and olfactomedin. FEBS Lett. 1997;413:349-353.
28. Adam MF, Belmouden A, Binisti P, et al. Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma. Hum Mol Genet. 1997;6:2091-2097.
29. Fingert JH, Clark AF, Craig JE, et al. Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:145-152.
30. Taniguchi F, Suzuki Y, Kurihara H, et al. Molecular cloning of the bovine MYOC and induction of its expression in trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2000;41:2070-2075.
31. Taguchi M, Kanno H, Kubota R, et al. Molecular cloning and expression profile of rat myocilin. Mol Genet Metab. 2000;70:75-80.
32. Russell P, Tamm ER, Grehn FJ, et al. The presence and properties of myocilin in the aqueous humor. Invest Ophthalmol Vis Sci. 2001;42:983-986.
33. Nguyen TD, Chen P, Huang WD, et al. Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells. J Biol Chem. 1998;273:6341-6350.
34. Snyder DA, Rivers AM, Yokoe H, et al. Olfactomedin: purification, characterization, and localization of a novel olfactory glycoprotein. Biochemistry (Mosc). 1991;30:9143-9153.
35. Karavanich C, Anholt RR. Evolution of olfactomedin. Structural constraints and conservation of primary sequence motifs. Ann NY Acad Sci. 1998;855:294-300.
36. Anholt RR, Petro AE, Rivers AM. Identification of a group of novel membrane proteins unique to chemosensory cilia of olfactory receptor cells. Biochemistry (Mosc). 1990;29:3366-3373.
37. Moreno TA, Bronner-Fraser M. The secreted glycoprotein Noelin-1 promotes neurogenesis in Xenopus. Dev Biol. 2001;240:340-360.
38. Karali A, Russell P, Stefani FH, et al. Localization of myocilin/trabecular meshwork-inducible glucocorticoid response protein in the human eye. Invest Ophthalmol Vis Sci. 2000;41:729-740.
39. Ricard CS, Agapova OA, Salvador-Silva M, et al. Expression of myocilin/TIGR in normal and glaucomatous primate optic nerves. Exp Eye Res. 2001;73:433-447.
40. Ohlmann A, Goldwich A, Flugel-Koch C, et al. Secreted glycoprotein myocilin is a component of the myelin sheath in peripheral nerves. Glia. 2003;43:128-140.
41. Kim BS, Savinova OV, Reedy MV, et al. Targeted disruption of the myocilin gene (Myoc) suggests that human glaucoma-causing mutations are gain of function. Mol Cell Biol. 2001;21:7707-7713.
42. Rao PV, Allingham RR, Epstein DL. TIGR/myocilin in human aqueous humor. Exp Eye Res. 2000;71:637-641.
43. Tamm ER, Russell P, Epstein DL, et al. Modulation of myocilin/TIGR expression in human trabecular meshwork. Invest Ophthalmol Vis Sci. 1999;40:2577-2582.
44. Wang X, Johnson DH. mRNA in situ hybridization of TIGR/MYOC in human trabecular meshwork. Invest Ophthalmol Vis Sci. 2000;41:1724-1729.
45. Takahashi H, Noda S, Mashima Y, et al. The myocilin (MYOC) gene expression in the human trabecular meshwork. Curr Eye Res. 2000;20:81-84.
46. Huang W, Jaroszewski J, Ortego J, et al. Expression of the TIGR gene in the iris, ciliary body, and trabecular meshwork of the human eye. Ophthalmic Genet. 2000;21:155-169.
47. Swiderski RE, Ross JL, Fingert JH, et al. Localization of MYOC transcripts in human eye and optic nerve by in situ hybridization. Invest Ophthalmol Vis Sci. 2000;41:3420-3428.
48. Alward WL, Fingert JH, Coote MA, et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). N Engl J Med. 1998;338:1022-1027.
49. Mackey DA, Healey DL, Fingert JH, et al. Glaucoma phenotype in pedigrees with the myocilin Thr377Met mutation. Arch Ophthalmol. 2003;121:1172-1180.
50. Wilkinson CH, van der Straaten D, Craig JE, et al. Tonography demonstrates reduced facility of outflow of aqueous humor in myocilin mutation carriers. J Glaucoma. 2003; 12:237-242.
51. Fautsch MP, Bahler CK, Jewison DJ, et al. Recombinant TIGR/MYOC increases outflow resistance in the human anterior segment. Invest Ophthalmol Vis Sci. 2000;41:4163-4168.
52. Borras T, Rowlette LL, Erzurum SC, et al. Adenoviral reporter gene transfer to the human trabecular meshwork does not alter aqueous humor outflow. Relevance for potential gene therapy of glaucoma. Gene Ther. 1999;6:515-524.
53. Johnson DH. Myocilin and glaucoma: a TIGR by the tail? Arch Ophthalmol. 2000;118: 974-978.
54. Caballero M, Rowlette LL, Borras T. Altered secretion of a TIGR/MYOC mutant lacking the olfactomedin domain. Biochim Biophys Acta. 2000;1502:447-460.
55. Caballero M, Borras T. Inefficient processing of an olfactomedin-deficient myocilin mutant: potential physiological relevance to glaucoma. Biochem Biophys Res Commun. 2001;282:662-670.
56. Epstein DL CM, Gonzalez P. Changes in human trabecular meshwork cells induced by overexpression of SPARC. Annual Meeting Abstract Search and Program Planner [on CD-ROM]. Association for Research in Vision and Ophthalmology Abstract 4025; 2002.
57. Alward WL. The genetics of open-angle glaucoma: the story of GLC1A and myocilin. Eye. 2000;14:429-436.
58. Lam DS, Leung YF, Chua JK, et al. Truncations in the TIGR gene in individuals with and without primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2000;41:1386-1391.
59. Wiggs JL, Vollrath D. Molecular and clinical evaluation of a patient hemizygous for TIGR/MYOC. Arch Ophthalmol. 2001;119:1674-1678.
60. Morissette J, Clepet C, Moisan S, et al. Homozygotes carrying an autosomal dominant TIGR mutation do not manifest glaucoma. Nat Genet. 1998;19:319-321.
61. Johnson WG. Metabolic interference and the + - heterozygote, a hypothetical form of simple inheritance which is neither dominant nor recessive. Am J Hum Genet. 1980; 32:374-386.
62. Bruttini M, Longo I, Frezzotti P, et al. Mutations in the myocilin gene in families with primary open-angle glaucoma and juvenile open-angle glaucoma. Arch Ophthalmol. 2003;121:1034-1038.
63. Jansson M, Marknell T, Tomic L, et al. Allelic variants in the MYOC/TIGR gene in patients with primary open-angle, exfoliative glaucoma and unaffected controls. Ophthalmic Genet. 2003;24:103-110.
64. Faucher M, Anctil JL, Rodrigue MA, et al. Founder TIGR/myocilin mutations for glaucoma in the Quebec population. Hum Mol Genet. 2002;11:2077-2090.
65. Vincent AL, Billingsley G, Buys Y, et al. Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. Am J Hum Genet. 2002;70:448-460.
66. Brown MD, Voljavec AS, Lott MT, et al. Leber's hereditary optic neuropathy: a model for mitochondrial neurodegenerative diseases. FASEB J. 1992;6:2791-2799.
67. Sarfarazi M, Child A, Stoilova D, et al. Localization of the fourth locus (GLC1E) for adult-onset primary open-angle glaucoma to the 10p15-p14 region. Am J Hum Genet. 1998;62:641-652.
68. Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science. 2002;295:1077-1079.
69. Alward WL, Kwon YH, Kawase K, et al. Evaluation of optineurin sequence variations in 1,048 patients with open-angle glaucoma. Am J Ophthalmol. 2003;136:904-910.
70. Leung YF, Fan BJ, Lam DS, et al. Different optineurin mutation pattern in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:3880-3884.
71. Wiggs JL, Auguste J, Allingham RR, et al. Lack of association of mutations in optineurin with disease in patients with adult-onset primary open-angle glaucoma. Arch Ophthalmol. 2003;121:1181-1183.
72. Li Y, Kang J, Horwitz MS. Interaction of an adenovirus E3 14. 7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains. Mol Cell Biol. 1998;18:1601-1610.
73. Vittitow J, Borras T. Expression of optineurin, a glaucoma-linked gene, is influenced by elevated intraocular pressure. Biochem Biophys Res Commun. 2002;298:67-74.
74. Armaly MF, Becker B. Intraocular pressure response to topical corticosteroids. Fed Proc. 1965;24:1274-1278.
75. Johnson D, Gottanka J, Flugel C, et al. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol. 1997;115:375-383.
76. Borras T, Rowlette LL, Tamm ER, et al. Effects of elevated intraocular pressure on outflow facility and TIGR/MYOC expression in perfused human anterior segments. Invest Ophthalmol Vis Sci. 2002;43:33-40.
77. Goldwich A, Ethier CR, Chan DW, et al. Perfusion with the olfactomedin domain of myocilin does not affect outflow facility. Invest Ophthalmol Vis Sci. 2003;44:1953-1961.
78. Gaton DD, Sagara T, Lindsey JD, et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol. 2001;119:1165-1170.
79. Bradley JM, Anderssohn AM, Colvis CM, et al. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalpha. Invest Ophthalmol Vis Sci. 2000;41:422-430.
80. Chandler PA, Grant WM. Lectures on Glaucoma. Philadelphia, PA: Lea & Febiger; 1965:431.
81. Chandler PA, Grant WM, Epstein DL. Chandler and Grant's Glaucoma. 3rd ed. Philadelphia, PA: Lea & Febiger; 1986:539.
82. deLuise VP, Anderson DR. Primary infantile glaucoma (congenital glaucoma). Surv Ophthalmol. 1983;28:1-19.
83. Turacli ME, Aktan SG, Sayli BS, et al. Therapeutical and genetical aspects of congenital glaucomas. Int Ophthalmol. 1992;16:359-362.
84. Anderson DR. The development of the trabecular meshwork and its abnormality in primary infantile glaucoma. Trans Am Ophthalmol Soc. 1981;79:458-485.
85. Shields MB. Textbook of Glaucoma. 4th ed. Baltimore, MD: Williams & Wilkins; 1998: 588.
86. Francois J. Congenital glaucoma and its inheritance. Ophthalmologica. 1980;181:61-73.
87. Jay B, Paterson G. The genetics of simple glaucoma. Trans Ophthalmol Soc UK 1970; 90:161-171.
88. Sarfarazi M, Akarsu AN, Hossain A, et al. Assignment of a locus (GLC3A) for primary congenital glaucoma (Buphthalmos) to 2p21 and evidence for genetic heterogeneity. Genomics. 1995;30:171-177.
89. Akarsu AN, Turacli ME, Aktan SG, et al. A second locus (GLC3B) for primary congenital glaucoma (Buphthalmos) maps to the 1p36 region. Hum Mol Genet. 1996;5: 1199-1203.
90. Stoilov I SM. The third genetic locus. (GLC3C) for primary congenital glaucoma (PCG) maps to chromosome 14q24.3. Annual Meeting Abstract Search and Program Planner [on CD-ROM]. Association for Research in Vision and Ophthalmology Abstract 4025; 2002.
91. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet. 1997;6:641-647.
92. Bejjani BA, Lewis RA, Tomey KF, et al. Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia. Am J Hum Genet. 1998;62:325-333.
93. Kakiuchi T, Isashiki Y, Nakao K, et al. A novel truncating mutation of cytochrome P4501B1 (CYP1B1) gene in primary infantile glaucoma. Am J Ophthalmol. 1999;128: 370-372.
94. Bejjani BA, Stockton DW, Lewis RA, et al. Multiple CYP1B1 mutations and incomplete penetrance in an inbred population segregating primary congenital glaucoma suggest frequent de novo events and a dominant modifier locus. Hum Mol Genet. 2000;9:367-374.
95. Sarfarazi M, Stoilov I. Molecular genetics of primary congenital glaucoma. Eye. 2000; 14:422-428.
96. Kakiuchi-Matsumoto T, Isashiki Y, Ohba N, et al. Cytochrome P450 1B1 gene mutations in Japanese patients with primary congenital glaucoma(1). Am J Ophthalmol. 2001;131:345-350.
97. Mashima Y, Suzuki Y, Sergeev Y, et al. Novel cytochrome P4501B1 (CYP1B1) gene mutations in Japanese patients with primary congenital glaucoma. Invest Ophthalmol Vis Sci. 2001;42:2211-2216.
98. Panicker SG, Reddy AB, Mandal AK, et al. Identification of novel mutations causing familial primary congenital glaucoma in Indian pedigrees. Invest Ophthalmol Vis Sci. 2002;43:1358-1366.
99. Stoilov IR, Costa VP, Vasconcellos JP, et al. Molecular genetics of primary congenital glaucoma in Brazil. Invest Ophthalmol Vis Sci. 2002;43:1820-1827.
100. Colomb E, Kaplan J, Garchon HJ. Novel cytochrome P450 1B1 (CYP1B1) mutations in patients with primary congenital glaucoma in France. Hum Mutat. 2003;22:496.
101. Ohtake Y, Tanino T, Suzuki Y, et al. Phenotype of cytochrome P4501B1 gene (CYP1B1) mutations in Japanese patients with primary congenital glaucoma. Br J Ophthalmol. 2003;87:302-304.
102. Martin SN, Sutherland J, Levin AV, et al. Molecular characterization of congenital glaucoma in a consanguineous Canadian community: a step towards preventing glaucoma related blindness. J Med Genet. 2000;37:422-427.
103. Murray GI, Melvin WT, Greenlee WF, et al. Regulation, function, and tissue-specific expression of cytochrome P450 CYP 1B1. Annu Rev Pharmacol Toxicol. 2001;41:297-316.
104. Hakkola J, Pasanen M, Pelkonen O, et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis. 1997;18:391-397.
105. Crespi CL, Penman BW, Steimel DT, et al. Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens. Mutagenesis. 1997;12:83-89.
106. Shimada T, Hayes CL, Yamazaki H, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 1996;56:2979-2984.
107. Sasaki M, Tanaka Y, Kaneuchi M, et al. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res. 2003;63:3913-3918.
108. Crofts FG, Sutter TR, Strickland PT. Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis. 1998;19:1969-1973.
109. Nebert DW. Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. Mol Endocrinol. 1991;5:1203-1214.
110. Schwartzman ML, Balazy M, Masferrer J, et al. 12(R)-hydroxyicosatetraenoic acid: a cytochrome-P450-dependent arachidonate metabolite that inhibits Na+, K+-ATPase in the cornea. Proc Natl Acad Sci USA. 1987;84:8125-8129.
111. Buters JT, Sakai S, Richter T, et al. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA. 1999; 96:1977-1982.
112. Libby RT, Smith RS, Savinova OV, et al. Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science. 2003;299:1578-1581.
113. Nishimura DY, Swiderski RE, Alward WL, et al. The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25. Nat Genet. 1998; 19:140-147.
114. Hong HK, Lass JH, Chakravarti A. Pleiotropic skeletal and ocular phenotypes of the mouse mutation congenital hydrocephalus (ch/Mf1) arise from a winged helix/forkhead transcription factor gene. Hum Mol Genet. 1999;8:625-637.
115. Smelser GK, Ozanics V. The development of the trabecular meshwork in primate eyes. Am J Ophthalmol. 1971;1:366-385.
116. Johnston MC, Noden DM, Hazelton RD, et al. Origins of avian ocular and periocular tissues. Exp Eye Res. 1979;29:27-43.
117. Chandler PA, Grant WM, Epstein DL, et al. Chandler and Grant's glaucoma. 4th ed. Baltimore, MD: Williams & Wilkins; 1997:670.
118. Shields MB. Axenfeld-Rieger syndrome: a theory of mechanism and distinctions from the iridocorneal endothelial syndrome. Trans Am Ophthalmol Soc. 1983;81:736-784.
119. Chisholm IA, Chudley AE. Autosomal dominant iridogoniodysgenesis with associated somatic anomalies: four-generation family with Rieger's syndrome. Br J Ophthalmol. 1983;67:529-534.
120. Walter MA. PITs and FOXes in ocular genetics: the Cogan lecture. Invest Ophthalmol Vis Sci. 2003;44:1402-1405.
121. Semina EV, Reiter R, Leysens NJ, et al. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet. 1996;14:392-399.
122. Murray JC, Bennett SR, Kwitek AE, et al. Linkage of Rieger syndrome to the region of the epidermal growth factor gene on chromosome 4. Nat Genet. 1992;2:46-49.
123. Mears AJ, Jordan T, Mirzayans F, et al. Mutations of the forkhead/winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anomaly. Am J Hum Genet. 1998;63:1316-1328.
124. Riise R, Storhaug K, Brondum-Nielsen K. Rieger syndrome is associated with PAX6 deletion. Acta Ophthalmol Scand. 2001;79:201-203.
125. Hanson IM, Fletcher JM, Jordan T, et al. Mutations at the PAX6 locus are found in heterogeneous anterior segment malformations including Peters' anomaly. Nat Genet. 1994;6:168-173.
126. Vincent A, Billingsley G, Priston M, et al. Phenotypic heterogeneity of CYP1B1: mutations in a patient with Peters anomaly. J Med Genet. 2001;38:324-326.
127. Hanes SD, Brent R. A genetic model for interaction of the homeodomain recognition helix with DNA. Science. 1991;251:426-430.
128. Hanes SD, Riddihough G, Ish-Horowicz D, et al. Specific DNA recognition and intersite spacing are critical for action of the bicoid morphogen. Mol Cell Biol. 1994;14: 3364-3375.
129. Gage PJ, Suh H, Camper SA. Dosage requirement of Pitx2 for development of multiple organs. Development. 1999;126:4643-4651.
130. Priston M, Kozlowski K, Gill D, et al. Functional analyses of two newly identified PITX2 mutants reveal a novel molecular mechanism for Axenfeld-Rieger syndrome. Hum Mol Genet. 2001;10:1631-1638.
131. Saadi I, Semina EV, Amendt BA, et al. Identification of a dominant negative homeodomain mutation in Rieger syndrome. J Biol Chem. 2001;276:23034-23041.
132. Lehmann OJ, Ebenezer ND, Ekong R, et al. Ocular developmental abnormalities and glaucoma associated with interstitial 6p25 duplications and deletions. Invest Ophthalmol Vis Sci. 2002;43:1843-1849.
133. Alward WL, Semina EV, Kalenak JW, et al. Autosomal dominant iris hypoplasia is caused by a mutation in the Rieger syndrome (RIEG/PITX2) gene. Am J Ophthalmol. 1998;125:98-100.
134. Kulak SC, Kozlowski K, Semina EV, et al. Mutation in the RIEG1 gene in patients with iridogoniodysgenesis syndrome. Hum Mol Genet. 1998;7:1113-1117.
135. Doward W, Perveen R, Lloyd IC, et al. A mutation in the RIEG1 gene associated with Peters' anomaly. J Med Genet. 1999;36:152-155.
136. Weigel D, Jackle H. The fork head domain: a novel DNA binding motif of eukaryotic transcription factors? Cell. 1990;63:455-456.
137. Larsson C, Hellqvist M, Pierrou S, et al. Chromosomal localization of six human forkhead genes, freac-1 (FKHL5),-3 (FKHL7),-4 (FKHL8),-5 (FKHL9),-6 (FKHL10), and -8 (FKHL12). Genomics. 1995;30:464-469.
138. Honkanen RA, Nishimura DY, Swiderski RE, et al. A family with Axenfeld-Rieger syndrome and Peters anomaly caused by a point mutation (Phe112Ser) in the FOXC1 gene. Am J Ophthalmol. 2003;135:368-375.
139. Smith RS, Zabaleta A, Kume T, et al. Haploinsufficiency of the transcription factors FOXC1 and FOXC2 results in aberrant ocular development. Hum Mol Genet. 2000;9: 1021-1032.
140. Kivlin JD, Fineman RM, Crandall AS, et al. Peters' anomaly as a consequence of genetic and nongenetic syndromes. Arch Ophthalmol. 1986;104:61-64.
141. Green JS, Johnson GJ. Congenital cataract with microcornea and Peters' anomaly as expressions of one autosomal dominant gene. Ophthalmic Paediatr Genet. 1986;7:187-194.
142. Jamieson RV, Perveen R, Kerr B, et al. Domain disruption and mutation of the bZIP transcription factor, MAF, associated with cataract, ocular anterior segment dysgenesis and coloboma. Hum Mol Genet. 2002;11:33-42.
143. Aung T, Ocaka L, Ebenezer ND, et al. A major marker for normal tension glaucoma: association with polymorphisms in the OPA1 gene. Hum Genet. 2002;110:52-56.
144. Copin B, Brezin AP, Valtot F, et al. Apolipoprotein E-promoter single-nucleotide polymorphisms affect the phenotype of primary open-angle glaucoma and demonstrate interaction with the myocilin gene. Am J Hum Genet. 2002;70:1575-1581.
145. Rivolta C, Sharon D, DeAngelis MM, et al. Retinitis pigmentosa and allied diseases: numerous diseases, genes, and inheritance patterns. Hum Mol Genet. 2002;11:1219-1227.
146. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7: 321-331.
147. Kawai SI, Vora S, Das S, et al. Modeling of risk factors for the degeneration of retinal ganglion cells after ischemia/reperfusion in rats: effects of age, caloric restriction, diabetes, pigmentation, and glaucoma. FASEB J. 2001;15:1285-1287.
148. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997;277:997-1003.